Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus.
From Cardiovascular Research Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, United Kingdom (R.F.S., W.A.E.P.); and Directorate of Cardiology and Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom (R.F.S., W.A.E.P.). r.f.storey@sheffield.ac.uk.
Robert F
RF
Storey
From Cardiovascular Research Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, United Kingdom (R.F.S., W.A.E.P.); and Directorate of Cardiology and Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom (R.F.S., W.A.E.P.).
William A E
WA
Parker
D054058:Acute Coronary Syndrome / Q000188:drug therapy; D000241:Adenosine / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects*; D003920:Diabetes Mellitus / Q000188:drug therapy; D006801:Humans; D062645:Percutaneous Coronary Intervention; D010879:Piperazines / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D000068799:Prasugrel Hydrochloride; D058921:Purinergic P2Y Receptor Antagonists / Q000494:pharmacology*; D013876:Thiophenes / Q000494:pharmacology; D013988:Ticlopidine / Q000494:pharmacology; D016896:Treatment Outcome
D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D013876:Thiophenes; D000068799:Prasugrel Hydrochloride; D000241:Adenosine; D013988:Ticlopidine
Editorials; diabetes mellitus; pharmacology; platelet activation; prasugrel hydrochloride; ticagrelor